Remedy Robotics Raises $62 Million Series B For Cardiovascular Robotic System Development

Remedy Robotics has raised $62 million in Series B funding to advance its AI-enabled endovascular robotic platform toward clinical trials and potential regulatory approval. DCVC led the round, with participation from UC Investments, Skip Capital and Hostplus. Existing investors Build Collective, Blackbird, Divergent Capital and KdT Ventures also participated.

The financing will support a planned pivotal trial with the University of California and development toward FDA approval for neurovascular intervention.

Remedy also plans prototype deployments across its clinical partner network, including work with SVIN Mission Thrombectomy and the Australian Stroke Alliance.

Its N1 System combines robotics, machine learning and computer vision. Intended capabilities include analyzing preoperative images, simulating procedures and registering three-dimensional images against two-dimensional images during intervention.

The platform is being designed for on-site, remote and potentially autonomous operation. Remedy is continuing development of its AI and autonomous functions.

The company works with more than 100 hospitals worldwide. In October 2025, it announced completion of remote neurointerventional procedures using the N1 System.

The system remains under development and is not currently available for sale or clinical use in any jurisdiction.

Remedy’s objective is to address limited access to specialists who perform endovascular procedures, particularly when distance from a treatment center delays emergency care.

The company’s clinical and research work has appeared in peer-reviewed neuroradiology journals. It holds 48 patents covering its platform, including machine learning applications in surgical robotics.

Headquartered in San Francisco, Remedy has worked with University of California clinical specialists since 2021.

The new capital supports the next stage of testing and development, with commercial deployment dependent on clinical results, regulatory progress and completion of the system.

KEY QUOTES

“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common. This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography.”

Dr. David Bell, CEO And Co-Founder Of Remedy Robotics

“Remedy Robotics represents a new generation of medical robotics and physical AI companies, focused not only on technical innovation, but on solving real-world challenges. We believe the company is uniquely positioned to redefine how life-saving intervention is delivered and are thrilled to support them as they advance toward broader clinical and commercial adoption.”

James Hardiman, General Partner At DCVC

“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy. We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”

Jake Sganga, Chief Technology Officer And Co-Founder Of Remedy Robotics

“Remedy is building the kind of company we look for at Blackbird: one with world-class technical talent, a massive global problem to solve, and the potential to create an entirely new category. We believe Remedy is uniquely positioned to transform how endovascular care is delivered, and we are excited to support the company through its next phase of growth.”

Michael Tolo, Partner At Blackbird